Etodolac (ETD) is a non-steroidal anti-inflammatory drug (NSAIDs). It has anti-inflammatory, analgesic, and anti-pyretic properties. The adverse effects of NSAIDs on the gastrointestinal tract (GIT) are gastric irritation and ulceration. So, in our research, we aim to enhance solubility which will lead to reducing side effects using the inclusion of complex techniques. Cyclodextrins (CDs) were used at a 1:1 drug: excipients molar ratio. All formulations were investigated by solubility and drug content studies and drug-polymer interactions by using thermal gravimetric analysis (TGA), and infrared spectroscopy (IR). The formulations showed improvement in insolubility. The extent of solubility enhancement was arranged in order as follows: HP-β-CD > α - CD > Sorbitol. IR studies approved no interaction between the drug and the carrier. TGA study approved the conversion of the drug to an amorphous state. It was concluded that α -CD and HP-β-CD can be used to improve the solubility of ETD.